We evaluated the efficacy and toxicity of different doses of donor T cells given with donor leukocyte infusions (DLI) as treatment for relapse of various hematologic malignancies after allogeneic bone marrow transplantation (BMT). We also studied whether DLI treatment was more effective if circulating T cells were exclusively of donor origin (complete donor T cell chimeras) as compared with T cells originating from both donor and recipient (mixed T cell chimeras). Twenty-eight patients were studied of whom 24 had a complete donor T cell chimerism. The malignancies were as follows: chronic myeloid leukemia (CML) in chronic phase (CP) (n = 9); more advanced CML (n = 5); multiple myeloma (MM) (n = 5); acute leukemia (AL) (n = 9). T cell doses varied from 0.1 ؋ 10 7 to 33 ؋ 10 7 T cells/kg. Eight patients received two to four DLI courses because they failed to respond to one course. Thirteen of 14 patients with CML, including four patients with more advanced CML, achieved complete remission (CR). All five patients with MM responded, including three CRs. Six patients (three with CML, three with MM) responded only after two to four DLI courses. Patients with CML-CP were likely to respond to as few as 1 ؋ 10 7 T cells/kg whereas patients with MM generally responded when they received у10 ؋ 10 7 T cells/kg. However, despite the infusion of high T cell doses (up to 32 ؋ 10 7 T cells/kg), practically all patients with AL failed to respond. The likelihood of response was strongly related to the occurrence of graft-versus-host disease (GVHD) in patients with CML and MM (P = 0.0002), although GVHD was not helpful for patients with AL. Higher T cell doses (у10 ؋ 10 7 /kg) induced serious GVHD (n = 17) and marrow aplasia (n = 5), and GVHD was directly or indirectly the cause of death for six patients. Finally, there were no obvious differences in responses between complete donor T cell chimeras and mixed T cell chimeras. Keywords: allogeneic BMT; donor leukocyte infusions; recurrent haematologic malignancies; T cell chimerism The ability of donor leukocyte infusions (DLI) to induce responses in recurrent hematologic malignancies after allogeneic bone marrow transplantation (BMT) seems to be dependent on at least two variables: (1) the kind of malignancy and (2) the number of T cells present in the DLI. Evidence for the first variable comes from a multicenter study reporting that DLI for recurrent leukemia after BMT can be effective in 80% of patients with chronic myeloid leukemia (CML) whereas this happens in only 20% of patients with acute myeloid leukemia or myelodysplastic syndrome.
The ability of donor leukocyte infusions (DLI) to induce responses in recurrent hematologic malignancies after allogeneic bone marrow transplantation (BMT) seems to be dependent on at least two variables: (1) the kind of malignancy and (2) the number of T cells present in the DLI. Evidence for the first variable comes from a multicenter study reporting that DLI for recurrent leukemia after BMT can be effective in 80% of patients with chronic myeloid leukemia (CML) whereas this happens in only 20% of patients with acute myeloid leukemia or myelodysplastic syndrome. 1 Evidence for the second variable comes from a study of escalating doses of donor T cells in DLI for patients with recurrent CML after BMT. 2 This is, of course, in line with the strong correlation between the number of donor T cells infused with the BMT procedure and the occurrence of both acute graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effect. [3] [4] [5] It is presently unknown whether patients whose circulating T cells are exclusively of donor origin (complete donor T cell chimerism) respond better to DLI than patients whose circulating donor T cells are admixed with patient T cells (mixed T cell chimerism). The possible importance of a complete donor T cell chimerism comes from a mouse model of BMT demonstrating that GVL reactivity occurs only after the achievement of a complete donor T cell chimerism. 6 It seems likely that immunologic tolerance of donor T cells to host T cells, manifested by the presence of a mixed T cell chimerism, will also result in tolerance to other host cells, including malignant cells. This is supported by the fact that patients with a mixed T cell chimerism have a markedly reduced incidence of acute GVHD. 7, 8 It is also possible that host T cells, present at the time of DLI, can counteract the effector functions of the infused donor T cells. To elucidate this issue, we report here the results of DLI in patients with a variety of recurrent non-T cell hematologic malignancies after BMT of whom the vast majority had a complete donor T cell chimerism when the DLI procedure took place. Because of the fact that only a few patients were mixed T cell chimeras, we compared our results in complete donor T cell chimeras also with those from a previous reported study 2 wherein the vast majority of patients had a mixed T cell chimerism at the time of DLI. Furthermore, as different hematologic malignancies probably require different doses of T cells in the DLI to induce responses, we also try to assess the appropriate T cell doses that are necessary for different malignancies with respect to efficacy and toxicity.
Materials and methods

Patients
Twenty-eight patients with chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and multiple myeloma (MM) after allogeneic BMT received donor leukocytes from their original marrow donors between March 1991 and July 1997. Results were analyzed as of 1 February 1998. Twenty-six donors were HLA-identical siblings and two donors were HLA-matched unrelated volunteers. Characteristics of patients and donors are reported in Table 1 .
The pretransplant conditioning regimens consisted of cyclophosphamide (120 mg/kg) and total body irradiation (600 cGy, on each of 2 successive days) in all patients, except for two patients with AML (UPN 204 and 222), who received cyclophosphamide (200 mg/kg) and busulfan (16 mg/kg). All patients received partially T cell-depleted marrow grafts, containing 1 ϫ 10 5 donor T cells/kg, as DLI = donor leukocyte infusion; CML = chronic myeloid leukemia; CP 1 or CP 2 = CML in first or second chronic phase; BT 2 = CML in second blastic phase; AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia; Ph = Philadelphia chromosome positive; CR 1 = first complete remission; Rel 1 = first relapse; MM = multiple myeloma; PR 2 = second partial remission; HR = hematologic response; NR = no response; PR = partial response; SD = stable disease; NE = not evaluable; AMSA ϩ cytarabine = amsacrine 150 mg/m 2 /day plus cytarabine 500 mg/m 2 twice a day, both given for 5 days; CHOP = cyclophosphamide, doxorubicin, vincristine, prednisone. described previously. 9 Furthermore, all patients received additional GVHD prophylaxis with a short course of cyclosporine post BMT. 9 Acute and chronic GVHD was diagnosed using standard criteria. 10 The patients were treated with clinical protocols approved by the local Investigational Review Board and gave informed consent.
Definitions
Complete remission (CR) of leukemias was defined as normalization of peripheral blood counts and bone marrow cellularity, absence of signs and symptoms of leukemia, and disappearance of cytogenetic abnormalities. For CML, CR included absence of Philadelphia chromosome in all metaphases and interphases analyzed with the FISH technique (at least 30 metaphases and 400 interphases were examined) and/or a negative result for polymerase chain reaction assays for BCR-ABL mRNA (sensitivity of 10 Ϫ3 in our laboratory).
Hematologic response (HR) for CML was defined as normalization of leukocyte counts, with no immature forms, and of platelet counts below 450 ϫ 10 9 /l, and disappearance of splenomegaly.
Partial remission (PR) of acute leukemias was defined as normalization of peripheral blood counts although the marrow contained between 5 and 20% blasts and/or persistence of extramedullary disease.
Stable disease (SD) of leukemias was defined solely as reduction of peripheral blood leukocytosis, without normalization of differential counts and/or disappearance of extramedullary disease.
For MM, complete remission was defined as Ͻ5% plasma cells in bilateral bone marrow biopsies, that had to be polyclonal by immune staining, together with disappearance of serum and urine M component by immune fixation. Partial remission (PR) was defined as у50% decrease in measurable M protein and bone marrow infiltration of monoclonal plasma cells.
No response (NR) of leukemias or MM was defined as response other than that of the previous definitions.
Complete chimerism was defined as the presence of nothing else but donor-type genetic markers in a subpopulation of peripheral blood cells that was analyzed, eg T cells. Mixed chimerism was defined as the presence of a mixture of donor and recipient peripheral blood cells in that subpopulation of peripheral blood cells.
Donor leukocyte infusions
Marrow donors underwent leukapheresis on a Haemonetics V50, intermittent-flow cell separator (Haemonetics Cooperation, Massachusetts, USA) or (since December 1995) on a Cobe continuous-flow cell separator (Cobe Laboratories, Gloucester, UK) and the leukocyte product obtained was immediately transfused without plasma or red blood cell depletion. The number of T cells given with DLI was lowered gradually over the years as more knowledge became available about efficacy and toxicity. When this form of adoptive immunotherapy was started in our BMT unit, one course of DLI consisted of a 5-days leukapheresis product. Subsequently, one DLI course consisted of a 3-days, 2-days, or 1-day leukapheresis product. Since August 1996, patients received a fixed number of T cells/kg obtained with a 1-day leukapheresis product. In principle, patients received the low dose of 1 ϫ 
Molecular analysis of chimerism
DNA from peripheral blood leukocytes (PBL) of patients and marrow donors were obtained before BMT and at regular intervals after BMT and at the time of relapse. Heparinized blood was obtained, mononuclear cells (MNC) were isolated by Ficoll-Hypaque density centrifugation and T and non-T fractions were acquired after sheep red blood cell rosetting of the MNC, and T cells were purified (always у98%) after treating the rosetted cells with 0.155 m NH 4 Cl. Cells were counted by Burker-Turk method and DNA was isolated by salting out. 11 Polymerase chain reaction (PCR) amplification of highly variable gene segments was used to discriminate between donor and recipient T cells. Initially, PCR amplification of four gene loci with nucleotide sequence repeats of 10 bp or more, the variable number of tandem repeats (VNTR), was performed by agarose-gel electrophoresis. The genetic markers used were apoB, pYNZ-22, pMCT-118 and SRY. 12 Subsequently, we used the combination of four short tandem repeats (STR) of 4 bp in a fluorescence-based PCR assay by gene-scan analysis. The genetic markers for this analysis were D19S253, HUMTHO, HUMVWFA 31/A and 388II. 13 The techniques of the PCR amplification of these genetic markers have been described previously. 12, 13 The gene-scanning method is more discriminative and sensitive than the agarose-gel electrophoresis (it detects 10 Ϫ4 to 10
Ϫ5
vs 10 Ϫ3 to 10 Ϫ4 of a minor cell population) and it provides the opportunity to discriminate donor from recipient cells in a (semi)quantitative way.
Results
Patient demographics
Diseases treated with DLI in 28 patients included: CML, 14 patients; AML, seven patients; ALL, two patients; MM, five patients (Table 1) . Except for two patients with CML (UPN 487 and 533), all patients with leukemia had achieved complete remission (CR) with the prior BMT procedure. Of five patients with MM, BMT induced CR in three patients and PR in another two patients (UPN 276 and 474). Time to relapse or disease progression and the occurrence of GVHD after BMT are shown in Table 1 .
At relapse after BMT, patients with CML had various phases of disease. Two patients (UPN 487 and 533) never achieved CR with the BMT procedure. Although a hematologic response was induced, they never achieved a cytogenetic remission. Moreover, the percentage of Ph-positive metaphases increased during follow-up and hematologic relapse did occur as well in both patients. Nine patients (UPN 160, 225, 362, 336, 377, 323, 201, 376 and 447) relapsed cytogenetically and hematologically. Four of them also had new cytogenetic abnormalities apart from the Ph chromosome, including two patients (UPN 225 and 377) with clinical manifestations of accelerated phase (AP) as well. Thus, nine patients were in chronic phase (CP) and two patients were in AP at the time of DLI. Three patients (UPN 256, 420 and 398) relapsed in blastic phase (BP). Therapy (hydroxyurea and/or interferon-␣) was given prior to the DLI procedure in four of 11 patients in CP or AP and resulted in hematologic response (HR), without a cytogenetic response, in three of them (Table 1 ). All three patients in BP were treated intensively with AMSA and/or cytarabine but only one (UPN 256) achieved PR. Three patients with AML were treated prior to DLI with AMSA plus cytarabine and two achieved CR. One patient with AML was treated mildly with hydroxyurea and thioguanine that resulted in (transient) stable disease. Five patients with ALL or AML were not treated with chemotherapy prior to DLI. One patient with MM was treated prior to DLI with one CHOP course because of rapidly progressive multiple extraskeletal plasmacytomas, however, progression continued. Four patients with MM were not treated prior to DLI.
T cell chimerism, analyzed at the time of DLI with PCR studies, demonstrated that 24 patients had a complete donor T cell chimerism, whereas four patients (UPN 474, 487, 533 and 447) had a mixed T cell chimerism. Three of them (UPN 474, 487 and 533) never achieved CR with the BMT procedure. At the time of DLI, the ratios of donor T cells to recipient T cells were approximately 67%:33%, 75%:25%, 80%:20% and 67%:33%, respectively.
Response to DLI
These data are summarized in Table 2 . Two patients with AML (UPN 222 and 352) were in CR (after retreatment with chemotherapy) at the time of DLI. However, UPN 222 had extramedullary relapse (in lymph nodes) after the first DLI course and received the second DLI course as treatment for the (second) relapse. So, six of seven patients with AML are evaluable for response to DLI. Only one of six patients achieved CR with DLI. This patient relapsed 6 months after the second DLI course, again extramedullary relapse, and died. The second patient (UPN 352) with AML who was in CR at the time of DLI, is still in CR with a CR duration beyond that obtained with the prior BMT procedure.
Two patients with recurrent Ph-positive ALL (UPN 330 and 589) were treated up-front with DLI. UPN 330 had extramedullary relapsed in skin, lymph nodes and testicles. The first DLI course induced an almost complete response of localisations in skin and lymph nodes whereas no response was observed in the testicles. The second DLI course was unsuccessful and the patient died of progressive disease. UPN 589 did not respond to DLI (from an unrelated donor) and died 7 weeks after DLI.
Five patients with MM are evaluable for response to DLI. Three patients responded completely, one (UPN 467) responded partially and one (UPN 388) has just started to respond. One patient (UPN 467) received with the first DLI course a low number of T cells (1 ϫ 10 6 /kg); this was given on a patient-based desire. The low T cell content induced partial remission while the second course with 1 ϫ 10 7 T cells/kg as well as the third course with 10 ϫ 10 7 T cells/kg failed. One patient (UPN 285) relapsed after the first DLI course (with 12 ϫ 10 7 T cells/kg) and received another three DLI courses (1 ϫ 10 7 , 10 ϫ 10 7 and 30 ϫ 10 7 T cells/kg, respectively) ( Table 2 ). The last course (with 30 ϫ 10 7 T cells/kg) reinduced a second CR. The median time to response in MM patients was 2 months (range 2-3 months). Fourteen patients with CML are evaluable for response (Table 2) . Three patients were in BP. Two patients with CML-BP achieved CR, one has a very short follow-up duration and one died from thrombotic thrombocytopenic purpura (TTP), probably related to chronic GVHD, almost 2 years after DLI. All patients with CML in CP (n = 9) or AP (n = 2) achieved CR. Three CML patients needed two DLI courses because of unresponsiveness to the first DLI course. All three (UPN 225, 447 and 533) achieved CR after the second DLI course. It may be important to note that one of them (UPN 225) responded only after removal of a huge spleen. The median time to response in CML patients was 2 months (range 1-5 months).
Toxicity
There were six treatment-related deaths. UPN 225 died of liver failure, 27 months after DLI. This patient had developed veno-occlusive disease of the liver after BMT and liver function tests were moderately disturbed at the time of relapse and even more disturbed at the time of DLI. Although repeated liver biopsies before and after DLI were inconclusive for chronic GVHD, the vanishing bile duct syndrome found at autopsy favored a diagnosis of GVHD. UPN 377 died from toxoplasmic meningoencephalitis during chronic GVHD (she omitted the co-trimoxazole prophylaxis). UPN 474 died from staphylococcus sepsis and pneumonia, occurring after the development of grade III acute GVHD and pancytopenia. UPN 256 died 22 months after DLI from TTP that occurred twice during extensive chronic GVHD. UPN 336 died from pericarditis and pneumonia that occurred also rather late (22 months after DLI) during smouldering extensive chronic GVHD. UPN 398 died from CNS bleeding during extensive chronic GVHD and pancytopenia.
There were five patients who developed pancytopenia, or, this complication occurred after five of 39 (13%) DLI courses given in 28 patients. One patient (UPN 474) is described above. Three patients (UPN 160, 398 and 533) needed a bone marrow boost because of severe bone marrow aplasia. A full recovery occurred in UPN 160. UPN 398 was recovering from pancytopenia when he died from CNS bleeding (his platelet counts were 40 ϫ 10 9 /l). UPN 533 is recovering from pancytopenia. The fifth patient (UPN 447) developed transient pancytopenia. None of the other patients developed pancytopenia nor any other cytopenia beyond grade I of the toxicity scale according to the common toxicity criteria (CTC-NCIC criteria). Three of the four patients who were mixed T cell chimeras developed marrow aplasia, whereas this occurred in two of 24 complete donor T cell chimeras. Furthermore, four of the five patients with marrow aplasia received у10 ϫ 10 7 T cells/kg with the DLI procedure.
Acute and/or chronic GVHD occurred after 24 of 39 (62%) DLI courses, or, this complication occurred in 22 of 28 (79%) patients. Apart from GVHD of the skin, occurring in 21 of 22 (95%) patients, disturbances of liver function tests developed in 14 of 21 (67%) patients and were imputed as GVHD of the liver. Biopsy of the liver was done in only one patient and was diagnostic for GVHD. Moreover, disturbances of liver function tests continued for a rather long time (above 1 year) in many of them, while other signs of GVHD had disappeared. The occurrence of GVHD was closely associated with the number of T cells infused with DLI (Table 2) ; one of 10 DLI courses with 1 ϫ 10 7 T cells/kg induced GVHD whereas this occurred after 22 of 28 courses with у2.5 ϫ 10 7 T cells/kg (P = 0.0003 by a two-tailed Fisher's test). The incidence of serious GVHD (ie у grade II acute GVHD and/or extensive chronic GVHD) was not significantly different (P = 0.66 by a two-tailed Stade Fisher's test) between patients who were treated with DLI within or beyond 1 year after BMT: five of seven (71%) patients vs 12 of 21 (57%) patients, respectively. Although the number of patients with a mixed T cell chimerism is low, there seems to be no difference in incidence or severity of GVHD between patients who were mixed T cell chimeras and those who were complete donor T cell chimeras.
Correlation between response, GVHD and numbers of T cells infused
This analysis is performed in CML and MM patients only because these diseases have proved to be sensitive to DLI. 1, 2, 14, 15 This means that 28 DLI courses in 19 patients can be evaluated for response and the occurrence of GVHD (Table 2 ). GVHD was induced by 17 DLI courses and 16 (94%) courses resulted in response, including 14 CRs. Eleven DLI courses did not induce GVHD and response was observed after only three courses (27%). The highly significant correlation between response and GVHD in these patients is shown in Table 3 (P = 0.0002, by a twotailed Fisher's test).
As is shown in Table 2 , patients with CML-CP can respond to the rather low numbers of 1 ϫ 10 7 T cells/kg (CR was achieved in three of five patients treated as such), whereas patients with MM seem to respond only after they were treated with у10 ϫ 10 7 T cells/kg. Relationship between GVHD and response is significant (P = 0.0002 by a two-tailed Fisher's test).
Of these 19 patients, four were mixed T cell chimeras and 15 were complete donor T cell chimeras. Similar CR rates were found in mixed T cell chimeras (all four achieved CR) as in complete T cell chimeras (12 of 14 evaluable patients achieved CR). Furthermore, all four mixed T cell chimeras became complete donor T cell chimeras following DLI (and responders).
Discussion
The aims of this study on DLI for recurrent malignancies after BMT are two-fold: (1) do different malignancies require different doses of donor T cells for response and (2) do patients with an already complete donor T cell chimerism respond better than patients with a mixed T cell chimerism? Our results show that patients with CML-CP are likely to respond to the low number of 1 ϫ 10 7 donor T cells/kg recipient weight, whereas patients with multiple myeloma (MM) require approximately 1 log more donor T cells, and that patients with acute leukemias (AL) generally respond very poorly even to high donor T cell doses. The issue of T cell dose given with DLI is very important because of the close relation between T cell dose and toxicity. In particular, more severe GVHD will be induced by higher T cell doses and cause severe morbidity and mortality.
That patients with CML-CP can respond to the low number of 1 ϫ 10 7 T cells/kg was suggested previously by the study of Mackinnon et al. 2 Our data show that patients with relapsed CML (in CP and AP) can start DLI treatment with 1 ϫ 10 7 T cells/kg although some relapsed CML patients will need T cell dose escalation. For patients with relapsed MM the initial donor T cell dose in the DLI should be 10 ϫ 10 7 T cells/kg. 15 It is presently unknown why MM patients need higher T cell numbers than CML-CP patients but this may be in line with the worse results of allogeneic BMT for patients with MM than for patients with leukemias. 16 Patients with full-blown relapse of AL are poor responders to DLI, irrespective of T cell numbers, as has also been shown by others. 1, 17 This is probably due to the incapacity of immunotherapy for rapid proliferating diseases though it may also be due to lack of time. Generally, it takes approximately 2 months for the antitumor effect of DLI to be induced, which is too long for patients with relapsed AL. In our series of AL patients there were only responses to DLI when the relapse had responded to previous chemotherapy or when the relapse was only extramedullary.
Practically all our patients (94%) who responded to DLI developed acute and/or chronic GVHD which is in agreement with a recent survey of 140 patients treated with DLI. 17 These observations argue for alloreactivity of donor T cells directed to (minor) histocompatibility antigens as the mechanism of response to DLI. Nevertheless, definitive conclusions about the mechanism of the antitumor response still need to be defined.
The toxicity of DLI is substantial: six of 28 patients in our series died from complications related to more severe GVHD. It should be stressed, however, that these lethal toxicities occurred mainly in those patients who were treated initially with high doses of donor T cells. Although the numbers of patients treated with escalating T cell doses are small, it seems that escalating T cell doses induce less severe GVHD than when it occurs following similar T cell numbers given as initial treatment. This point needs confirmation in larger series of patients.
Concerning the issue of response and presence or absence of complete donor T cell chimerism, our data suggest that there is no difference in response between complete T cell chimeras and mixed T cell chimeras. However, because of the fact that 24 of 28 patients were complete donor T cell chimeras we have also compared the responses in our patients with those reported in the study of Mackinnon et al 2 whose patients were mainly mixed T cell chimeras. The response rate in that study (17 of 20 mixed T cell chimeras achieved CR), containing CML patients only, is comparable to what we have found in complete donor T cell chimeras. It is not possible, because of the limited number of mixed T cell chimeras, to make clear statements about differences in toxicities between complete donor T cell chimeras and mixed T cell chimeras. Nevertheless, it is remarkable that three of four (75%) mixed T cell chimeras developed marrow aplasia while it occurs in only two of 24 (18%) complete T cell chimeras. A recent report has shown that marrow aplasia after DLI is unlikely to occur when donor-derived hematopoiesis at the time of DLI is still clearly present. 18 In summary, patients with CML (in CP and AP) and patients with MM who have relapsed after BMT are very likely to respond to DLI and the starting T cell dose can be as low as 1 ϫ 10 7 T cells/kg for patients with CML whereas this has to be approximately 1 log higher for patients with MM. Patients with AL in full-blown relapse need tumor reduction before DLI. Furthermore, mixed T cell chimeras probably respond as well as complete donor T cell chimeras to DLI. The minimal content of donor T cells in the mixed T cell chimerism that is mandatory for allowing DLI to be effective remains to be determined.
